Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCALOP: Gemcitabine vs Capecitabine Chemoradiotherapy in Pancreatic Cancer
NCT01032057Phase 2Completed
- Start
- Jul 2009
- Primary completion
- Jan 2013
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of gemcitabine and capecitabine in pancreatic cancer (PC) (2 arms). Primary endpoint: Progression-Free Survival at 39 weeks. Started Jul 2009; status: completed.
02
Drugs
gemcitabinecapecitabine
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT01032057.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01032057.